Inmazeb

E468966

Inmazeb is an FDA-approved monoclonal antibody cocktail used to treat infections caused by Zaire ebolavirus.

Try in SPARQL Jump to: Statements Referenced by

Statements (49)

Predicate Object
instanceOf FDA-approved drug
antiviral drug
biologic medicinal product
monoclonal antibody cocktail
prescription drug
adverseEffect chills
diarrhea
hypotension
hypoxia
nausea
pyrexia
shivering
tachycardia
vomiting
approvalDate 2020
approvalStatus approved
approvalType FDA-approved
blackBoxWarning hypersensitivity reactions
infusion-related reactions
countryOfApproval United States of America NERFINISHED
dosageForm solution for intravenous infusion
hasATCCode J06BD
hasComponent atoltivimab NERFINISHED
maftivimab NERFINISHED
odesivimab NERFINISHED
hasINN atoltivimab
maftivimab NERFINISHED
odesivimab NERFINISHED
indication treatment of infection caused by Zaire ebolavirus
isCombinationProduct true
isFirstInClass first FDA-approved treatment for Zaire ebolavirus infection
isHumanMonoclonalAntibody true
lactationUse caution advised
legalStatus prescription only
mechanismOfAction binds to Zaire ebolavirus glycoprotein
neutralizes Zaire ebolavirus
pharmacologicalClass antiviral monoclonal antibody
monoclonal antibody
pregnancyCategory insufficient human data
regulatoryAgencyApproval U.S. Food and Drug Administration NERFINISHED
riskPopulation hospitalized patients with Zaire ebolavirus infection
routeOfAdministration intravenous infusion
storageCondition refrigerated
targetOrganism Zaire ebolavirus NERFINISHED
therapeuticArea infectious disease
virology
treats Ebola virus disease caused by Zaire ebolavirus
Zaire ebolavirus infection
usedIn treatment of Ebola virus disease outbreaks

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

REGN-EB3 brandName Inmazeb